| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1526-4610.2007.00950.X |
| P698 | PubMed publication ID | 18052949 |
| P50 | author | David W Dodick | Q78768282 |
| Stephen D. Silberstein | Q78771344 | ||
| P2093 | author name string | Concetta Crivera | |
| Lian Mao | |||
| Joel Saper | |||
| Ninan T Mathew | |||
| Marcia F T Rupnow | |||
| Alan M Rapoport | |||
| Roger K Cady | |||
| Gary Finlayson | |||
| Steven J Greenberg | |||
| Joseph Hulihan | |||
| Fred G Freitag | |||
| P2860 | cites work | Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability | Q33941878 |
| Quality of life in chronic daily headache: a study in a general population. | Q51958113 | ||
| P433 | issue | 10 | |
| P921 | main subject | migraine | Q133823 |
| quality of life | Q13100823 | ||
| P304 | page(s) | 1398-1408 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Headache | Q5689497 |
| P1476 | title | The impact of topiramate on health-related quality of life indicators in chronic migraine | |
| P478 | volume | 47 |
| Q37176670 | Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life |
| Q47970385 | Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs). |
| Q38889450 | Chronic migraine: risk factors, mechanisms and treatment |
| Q34200361 | Clinical pharmacology of topiramate in migraine prevention |
| Q40090340 | Effect of Atlas Vertebrae Realignment in Subjects with Migraine: An Observational Pilot Study |
| Q37237787 | Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate |
| Q64898719 | Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. |
| Q48765812 | EuroQol (EQ-5D) health utility scores for patients with migraine |
| Q34387249 | Influence of treatments for migraine on quality of life: literature integrative review |
| Q37322222 | Medication overuse headache: awareness, detection and treatment |
| Q37643679 | Migraine and functional impairment |
| Q37999053 | OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine |
| Q33661856 | OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program |
| Q37121894 | OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program |
| Q92303364 | Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine |
| Q90730011 | Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders |
| Q37661479 | Role of antiepileptic drugs as preventive agents for migraine |
| Q39248893 | Suppressive effect of chronic peroral topiramate on potassium-induced cortical spreading depression in rats |
| Q38235953 | Topiramate and cognitive impairment: evidence and clinical implications |
| Q39024628 | Topiramate in Migraine Prevention: A 2016 Perspective |
| Q35658657 | Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders |
| Q91593067 | Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability |
| Q37188633 | When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis? |
Search more.